Association Between Tumor Size and Prognosis in Bladder Cancer: Novel Classifications and Insights from a SEER Database Analysis

Overview

Journal Front Surg

Specialty General Surgery

Date 2024 Dec 10

PMID 39654874

Authors

Yige Jia

Kan Wu

Xiang Li

Affiliations

Soon will be listed here.

Abstract

Objective: Although tumor size is an essential oncologic feature, it is often underutilized in diagnosing and treating bladder cancer (BC). This study investigates the relationship between tumor size and BC prognosis, aiming to enhance clinical applications.

Methods: BC patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015). Cox proportional hazard models were conducted to identify prognostic factors, and restricted cubic splines (RCS) were used to assess the relationship between tumor size and survival outcomes. The Kaplan-Meier method and multivariate COX models were utilized to estimate the effect of the classification scheme.

Results: A total of 69,478 patients with BC were evaluated from the SEER database. Larger tumor size, recent diagnosis, older age, high pathologic grade, variant histology, advanced T stages, positive lymph node status, and receipt of radiotherapy and chemotherapy were associated with worse overall and cancer-specific survival. RCS curves of each stage showed that the relationship between tumor size and prognosis was non-linear. Optimal cut-off points were identified based on the shape of RCS curves, suggesting new classifications of tumor size: 2.5 cm and 5 cm for Ta, 3 cm and 5 cm for T1, and 4 cm and 6 cm for T2.

Conclusions: Incorporating tumor size into prognostic evaluations can enhance bladder cancer risk stratification. Further research is needed to validate these findings and improve personalized treatment strategies.

References

Claps F, Biasatti A, Di Gianfrancesco L, Ongaro L, Giannarini G, Pavan N . The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature. J Clin Med. 2024; 13(15). PMC: 11313590. DOI: 10.3390/jcm13154349. View

Lee A, Lee H, Huang H, Ho H, Chen K . Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size. Int J Urol. 2019; 26(4):481-486. DOI: 10.1111/iju.13913. View

Gellert L, Warrick J, Al-Ahmadie H . Urothelial carcinoma with squamous differentiation--the pathologists׳ perspective. Urol Oncol. 2015; 33(10):437-43. DOI: 10.1016/j.urolonc.2015.07.018. View

Colombo R, Hurle R, Moschini M, Freschi M, Colombo P, Colecchia M . Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer. Eur Urol Focus. 2017; 4(1):87-93. DOI: 10.1016/j.euf.2016.06.004. View

Kamoun A, De Reynies A, Allory Y, Sjodahl G, Robertson A, Seiler R . A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2019; 77(4):420-433. PMC: 7690647. DOI: 10.1016/j.eururo.2019.09.006. View

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View

van Rhijn B, van der Kwast T, Alkhateeb S, Fleshner N, van Leenders G, Bostrom P . A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol. 2011; 61(2):378-84. DOI: 10.1016/j.eururo.2011.10.026. View

Chen X, Xu R, He D, Zhang Y, Chen H, Zhu Y . CD8 T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer. Oncogene. 2021; 40(43):6223-6234. DOI: 10.1038/s41388-021-02019-6. View

Humayun-Zakaria N, Ward D, Arnold R, Bryan R . Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?. Transl Androl Urol. 2021; 10(6):2787-2808. PMC: 8261432. DOI: 10.21037/tau-20-1327. View

10.

Comperat E, Amin M, Cathomas R, Choudhury A, De Santis M, Kamat A . Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022; 400(10364):1712-1721. DOI: 10.1016/S0140-6736(22)01188-6. View

11.

Mori K, Abufaraj M, Mostafaei H, Quhal F, Karakiewicz P, Briganti A . A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. J Urol. 2020; 204(6):1129-1140. DOI: 10.1097/JU.0000000000001305. View

12.

Chen X, Chen H, Yao H, Zhao K, Zhang Y, He D . Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer. Oncogene. 2021; 40(45):6381-6393. DOI: 10.1038/s41388-021-02024-9. View

13.

Claps F, Pavan N, Ongaro L, Tierno D, Grassi G, Trombetta C . BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets. Int J Mol Sci. 2023; 24(16). PMC: 10454200. DOI: 10.3390/ijms241612596. View

14.

Kurth K, Tunn U, Ay R, Schroder F, Pavone-Macaluso M, Debruyne F . Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol. 1997; 158(2):378-84. DOI: 10.1016/s0022-5347(01)64484-7. View

15.

Chang S, Boorjian S, Chou R, Clark P, Daneshmand S, Konety B . Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016; 196(4):1021-9. DOI: 10.1016/j.juro.2016.06.049. View

16.

Oosterlinck W, Kurth K, Schroder F, Bultinck J, Hammond B, Sylvester R . A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary.... J Urol. 1993; 149(4):749-52. DOI: 10.1016/s0022-5347(17)36198-0. View

17.

Babjuk M, Burger M, Capoun O, Cohen D, Comperat E, Dominguez Escrig J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2021; 81(1):75-94. DOI: 10.1016/j.eururo.2021.08.010. View

18.

Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M . Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020; 18(3):329-354. DOI: 10.6004/jnccn.2020.0011. View

19.

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

20.

Cheng L, NEUMANN R, Scherer B, Weaver A, Leibovich B, Nehra A . Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. Cancer. 1999; 85(12):2638-47. DOI: 10.1002/(sici)1097-0142(19990615)85:12<2638::aid-cncr21>3.0.co;2-v. View